» Articles » PMID: 38235419

Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14)

Overview
Publisher Dove Medical Press
Specialty Health Services
Date 2024 Jan 18
PMID 38235419
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Approximately 24% of hospitalized stage 2-3 acute kidney injury (AKI) patients will develop persistent severe AKI (PS-AKI), defined as KDIGO stage 3 AKI lasting ≥3 days or with death in ≤3 days or stage 2 or 3 AKI with dialysis in ≤3 days, leading to worse outcomes and higher costs. There is currently no consensus on an intervention that effectively reverts the course of AKI and prevents PS-AKI in the population with stage 2-3 AKI. This study explores the cost-utility of biomarkers predicting PS-AKI, under the assumption that such intervention exists by comparing C-C motif chemokine ligand 14 (CCL14) to hospital standard of care (SOC) alone.

Methods: The analysis combined a 90-day decision tree using CCL14 operating characteristics to predict PS-AKI and clinical outcomes in 66-year-old patients, and a Markov cohort estimating lifetime costs and quality-adjusted life years (QALYs). Cost and QALYs from admission, 30-day readmission, intensive care, dialysis, and death were compared. Clinical and cost inputs were informed by a large retrospective cohort of US hospitals in the PINC AI Healthcare Database. Inputs and assumptions were challenged in deterministic and probabilistic sensitivity analyses. Two-way analyses were used to explore the efficacy and costs of an intervention preventing PS-AKI.

Results: Depending on selected costs and early intervention efficacy, CCL14-directed care led to lower costs and more QALYs (dominating) or was cost-effective at the $50,000/QALY threshold. Assuming the intervention would avoid 10% of PS-AKI complications in AKI stage 2-3 patients identified as true positive resulted in 0.066 additional QALYs and $486 reduced costs. Results were robust to substantial parameter variation.

Conclusion: The analysis suggests that in the presence of an efficacious intervention preventing PS-AKI, identifying people at risk using CCL14 in addition to SOC is likely to represent a cost-effective use of resources.

Citing Articles

Biomarkers in acute kidney injury.

Ostermann M, Legrand M, Meersch M, Srisawat N, Zarbock A, Kellum J Ann Intensive Care. 2024; 14(1):145.

PMID: 39279017 PMC: 11402890. DOI: 10.1186/s13613-024-01360-9.

References
1.
Koyner J, Chawla L, Bihorac A, Gunnerson K, Schroeder R, Demirjian S . Performance of a Standardized Clinical Assay for Urinary C-C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury. Kidney360. 2022; 3(7):1158-1168. PMC: 9337886. DOI: 10.34067/KID.0008002021. View

2.
Kullmar M, Weiss R, Ostermann M, Campos S, Grau Novellas N, Thomson G . A Multinational Observational Study Exploring Adherence With the Kidney Disease: Improving Global Outcomes Recommendations for Prevention of Acute Kidney Injury After Cardiac Surgery. Anesth Analg. 2020; 130(4):910-916. DOI: 10.1213/ANE.0000000000004642. View

3.
Kellum J . Diagnostic Criteria for Acute Kidney Injury: Present and Future. Crit Care Clin. 2015; 31(4):621-32. PMC: 4584412. DOI: 10.1016/j.ccc.2015.06.001. View

4.
Koyner J, Mackey R, Rosenthal N, Carabuena L, Kampf J, Echeverri J . Health Care Resource Utilization and Costs of Persistent Severe Acute Kidney Injury (PS-AKI) Among Hospitalized Stage 2/3 AKI Patients. Kidney360. 2023; 4(3):316-325. PMC: 10103312. DOI: 10.34067/KID.0005552022. View

5.
Susantitaphong P, Cruz D, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I . World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol. 2013; 8(9):1482-93. PMC: 3805065. DOI: 10.2215/CJN.00710113. View